December 23, 2015.
FDA News reports that FDA has granted priority review status to PaxVax’s single-dose cholera vaccine Vaxchora.
The Agency has identified cholera as one of the eligible neglected tropical diseases under its priority review voucher program. The potential of being granted a voucher was a significant incentive for PaxVax to develop the vaccine for the U.S. market, the company says.
If licensed, Vaxchora would be the only vaccine against cholera approved in the U.S.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.